Goldman Sachs has initiated coverage of generic pharmaceutical stocks, highlighting the sector's strong long-term potential despite recent volatility.
Analyst Matt Dellatorre points to a mix of company-specific challenges—such as fiscal 2025 guidance—and broader industry concerns like…